Low sales, high cost: Melinta slashes HQ research staff as it struggles to grow antibiotics revenue
Look to Melinta Therapeutics for the latest sign of economic trouble in the antibiotics field.
Exactly a year after the Connecticut drugmaker executed a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.